Graft-versus-host disease (GVHD)

What is Graft-versus-host disease (GVHD)?

Graft-versus-host disease, or GVHD, is a serious complication that can happen after a bone marrow or stem cell transplant. When someone receives donor cells during a transplant, those new immune cells are supposed to help fight disease. But sometimes the donor cells see the recipient's body as foreign and start attacking healthy tissues and organs.

GVHD can be acute or chronic. Acute GVHD usually develops within the first 100 days after transplant. Chronic GVHD can occur later, sometimes months or even years after the procedure. Both types can affect multiple organs including the skin, liver, digestive tract, and other tissues.

This condition is different from transplant rejection. In rejection, the recipient's body attacks the donor cells. In GVHD, the donor cells attack the recipient. Understanding this difference helps doctors monitor transplant patients and catch problems early.

Immune Cell Function

Reveal how well your immune system works
Pinpoint why you might feel constantly tired
Expose hidden infections or immune issues

^$1,179

Symptoms

Skin rash or redness, sometimes with blistering or peeling
Yellowing of the skin or eyes from liver inflammation
Stomach pain, nausea, vomiting, or diarrhea
Dry mouth and difficulty swallowing
Dry, irritated, or burning eyes
Fatigue and general weakness
Loss of appetite and weight loss
Joint stiffness or muscle tightness in chronic GVHD
Shortness of breath or lung problems
Changes in nail texture or hair loss

Some people develop mild symptoms while others experience severe reactions. Early signs can be subtle, which is why close monitoring after transplant is essential.

Causes and risk factors

GVHD happens when donor immune cells, called T cells, recognize the recipient's body tissues as foreign. The more genetically different the donor and recipient are, the higher the risk. Even with perfectly matched siblings, GVHD can still occur because no two people are genetically identical. The donor cells may attack the skin, digestive system, liver, or other organs as they try to eliminate what they perceive as threats.

Risk factors include donor and recipient tissue mismatch, older recipient age, female donor to male recipient, use of donor blood with active immune cells, and the intensity of pre-transplant chemotherapy or radiation. The type of transplant also matters. Transplants from unrelated donors or using peripheral blood stem cells carry higher GVHD risk than bone marrow from matched siblings.

How it's diagnosed

Doctors diagnose GVHD based on symptoms, physical exam findings, and timing after transplant. Blood tests help assess organ function and inflammation, particularly liver enzymes and immune markers. A skin biopsy, liver biopsy, or endoscopy of the digestive tract can confirm the diagnosis by showing characteristic tissue damage patterns from immune attack.

Monitoring immune cell function and organ health is essential after any stem cell or bone marrow transplant. Talk to your transplant team about which tests you need and how often. While standard blood panels can track organ function, specialized immunology testing may be required to assess your specific risk and response to treatment.

Treatment options

Immunosuppressive medications to calm the donor immune cells and reduce inflammation
Corticosteroids like prednisone as first-line treatment for most GVHD cases
Additional medications if steroids alone are not effective, including calcineurin inhibitors or newer targeted therapies
Skin care with gentle moisturizers and sun protection for skin involvement
Nutritional support and dietary changes for digestive symptoms
Physical therapy to maintain mobility and prevent joint stiffness in chronic GVHD
Eye drops and oral care for dryness and irritation
Infection prevention measures since immunosuppressive drugs increase infection risk
Regular monitoring and follow-up with your transplant team
Participation in support groups or counseling to manage the emotional impact

Frequently asked questions

Acute GVHD typically occurs within the first 100 days after transplant and often affects the skin, liver, and digestive tract. Chronic GVHD develops later, sometimes months or years post-transplant, and can cause more widespread problems including joint stiffness, dry eyes, and lung issues. The two types require different treatment approaches and have different long-term outlooks.

Doctors try to prevent GVHD by carefully matching donors and recipients and giving immunosuppressive medications after transplant. Common prevention drugs include tacrolimus, cyclosporine, and methotrexate. Despite these efforts, GVHD still occurs in many transplant patients because perfect prevention is not yet possible. The goal is to balance preventing GVHD while allowing donor cells to fight cancer or disease.

GVHD can range from mild to life-threatening depending on severity and organs affected. Mild cases may cause only skin rash or minor digestive issues that respond well to treatment. Severe GVHD can cause serious organ damage and requires intensive immunosuppressive therapy. Close monitoring and early treatment improve outcomes significantly.

No, not everyone develops GVHD after transplant. The risk varies based on donor match quality, transplant type, and prevention medications used. About 30 to 50 percent of transplant recipients develop some degree of acute GVHD. Chronic GVHD occurs in roughly 30 to 70 percent of long-term transplant survivors.

Mild acute GVHD sometimes resolves with minimal treatment, but most cases require immunosuppressive medications. Chronic GVHD rarely goes away without treatment and may need long-term management. Some patients experience remission where symptoms disappear or become very mild, allowing gradual reduction of medications under careful medical supervision.

Blood tests for GVHD typically include liver function tests to check for liver damage and complete blood counts to assess overall health. Immune cell function testing can help evaluate how donor cells are behaving. Inflammation markers and organ-specific tests guide treatment decisions. Your transplant team will create a personalized monitoring schedule based on your symptoms and risk factors.

Treatment duration varies widely depending on GVHD severity and response to therapy. Some patients need medication for only a few months, while others require years of immunosuppressive treatment. Doctors gradually reduce medication doses when symptoms improve, watching carefully for any signs of flare-up. Never stop or change GVHD medications without consulting your transplant team.

Many people with mild to moderate GVHD can maintain normal activities including work and school. The decision depends on symptom severity, medication side effects, and infection risk. Immunosuppressive drugs increase vulnerability to infections, so avoiding crowded places during flu season may be wise. Discuss your specific situation with your transplant team to create a safe activity plan.

For digestive GVHD, a low-fiber, bland diet often reduces symptoms like diarrhea and cramping. Avoiding raw fruits and vegetables, spicy foods, and high-fat items can help. Some patients benefit from lactose-free diets or eating smaller, more frequent meals. Work with a dietitian who specializes in transplant care to develop a nutrition plan that supports healing while preventing infection.

There is no guaranteed cure for GVHD, but many patients achieve remission with proper treatment. Research continues into new therapies that better control the immune response without increasing infection risk. Some newer medications show promise for steroid-resistant GVHD. The focus is on managing symptoms, protecting organ function, and maintaining quality of life while supporting the beneficial effects of the transplant.